Arveles 50 mg/2 ml Ampul and Upadacitinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
The JAK-inhibitor label flags gastrointestinal-perforation risk in patients taking systemic NSAIDs.
Clinical significance and safety
Arveles 50 mg/2 ml Ampul contains a systemic nonsteroidal anti-inflammatory drug. Upadacitinib labeling calls for attention to gastrointestinal-perforation risk, especially with diverticulitis or other relevant history; this is not a universal contraindication to every NSAID prescription. New or severe abdominal pain warrants prompt assessment, and the prescriber should review the complete regimen.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.